FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is medication, possessing anti-helicobacter action. As anti-helicobacter medication claimed is low-etherificated non-starch polysaccharide - calcium pectate, which has the following physic-chemical characteristics: etherification degree - 1.2%, molecular weight - 39.3 kDa, content of anghydro galacturonic acid - 67.3% and calcium - 38 mg/g sample. Substance was earlier known as prebiotic and by its preventive action on development of ulcerous lesions of stomach, caused by intake of non-steroid anti-inflammatory medications. Demonstrated is expressed action in vitro of calcium pectate on Helicobacter pylori culture.
EFFECT: detected activity with account of earlier known one makes it possible to consider calcium pectate a universal medication for treatment of ulcer disease of stomach and duodenum, other gastrointestinal diseases, associated with Helicobacter pylori.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT WITH PREBIOTIC ACTIVITY | 2007 |
|
RU2366429C2 |
| ANTI-HELICOBACTER AGENT AND METHOD FOR USE THEREOF | 2018 |
|
RU2713154C1 |
| METHOD FOR TREATING HELICOBACTER PYLORI-ASSOCIATED ULCEROUS GASTRIC AND DUODENAL DISEASE | 2006 |
|
RU2308949C1 |
| MEDICINAL AGENT, PHARMACEUTICAL COMPOSITION, HELICOBACTER PYLORI GROWTH INHIBITOR AND METHOD OF ANTIHELICOBACTERY THERAPY | 2007 |
|
RU2367458C1 |
| METHOD FOR ERADICATION OF HELICOBACTER PYLORI BACTERIA IN EXPERIMENTAL HELICOBACTERIOSIS IN CONVENTIONAL WHITE MICE AND A MEANS FOR ITS IMPLEMENTATION | 2020 |
|
RU2746590C1 |
| ANTIULCER AGENT | 2022 |
|
RU2795979C1 |
| METHOD FOR TREATING THE CASES OF GASTRIC AND DUODENAL PEPTIC ULCER | 2004 |
|
RU2250767C1 |
| METHOD FOR TREATING GASTRIC AND DUODENAL ULCEROUS DISEASE | 2005 |
|
RU2304967C2 |
| METHOD OF TREATMENT OF PEPTIC ULCER OF STOMACH AND DUODENUM, ASSOCIATED WITH Helicobacter pylori | 2007 |
|
RU2352346C2 |
| METHOD OF PRE-OPERATION PREPARATION OF PATIENTS WITH ULCER DISEASE ASSOCIATED WITH Helicobacter pylori | 2011 |
|
RU2448728C1 |
